68211-15-4

Basic information

• Product Name: 6-bromo-4-chlorocinnoline
• Synonyms: 6-bromo-4-chlorocinnoline;Cinnoline, 6-broMo-4-chloro-
• CAS NO: 68211-15-4
• Molecular Formula: C₈H₄BrClN₂
• Molecular Weight: 243.5
• Mol File: 68211-15-4.mol
• Article Data: 9

Chemical Properties

• Melting Point: 127-128℃
• Boiling Point: 214.417 °C at 760 mmHg
• Flash Point: 83.477 °C
• Appearance: /
• Density: 1.762
• Vapor Pressure: 0.228mmHg at 25°C
• Refractive Index: 1.691
• PKA: -1.08±0.10(Predicted)
• CAS DataBase Reference: 6-bromo-4-chlorocinnoline(CAS DataBase Reference)
• NIST Chemistry Reference: 6-bromo-4-chlorocinnoline(68211-15-4)
• EPA Substance Registry System: 6-bromo-4-chlorocinnoline(68211-15-4)

Safety Data

• Hazardous Substances Data: 68211-15-4(Hazardous Substances Data)

Usage

General Description

6-bromo-4-chlorocinnoline is a chemical compound with the molecular formula C9H5BrClN. It is a heterocyclic compound that contains a fused ring system consisting of a benzene ring fused to a pyridine ring and substituted with bromine and chlorine atoms. 6-bromo-4-chlorocinnoline is used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. It has also been studied for its potential anti-cancer properties. 6-bromo-4-chlorocinnoline is a white solid that is insoluble in water but soluble in organic solvents. Its structure and properties make it an important building block in organic synthesis and medicinal chemistry.

InChI:InChI=1/C8H4BrClN2/c9-5-1-2-8-6(3-5)7(10)4-11-12-8/h1-4H

Upstream product

• 876-88-0 6-bromo-1H-cinnolin-4-one 
• 876-88-0 6-bromocinnolin-4-ol 
• 29124-56-9 1-(2-amino-5-bromophenyl)ethanone 
• 551-93-9 2-aminoacetophenone 
• 5234-26-4 N-(2-acetylphenyl)acetamide 
• 29124-64-9 N-(2-acetyl-4-bromophenyl)acetamide 

Downstream Products

• 854891-19-3 6-bromo-4-phenoxy-cinnoline 

Relevant articles and documents

Cnoline compound PI3K kinase inhibitor as well as preparation method and application thereof in pharmacy

The invention provides a cinnoline compound PI3K kinase inhibitor as shown in a formula I. In the cinnoline compound PI3K kinase inhibitor, and R1, R2 and R3 are defined in the specification. The invention also provides a pharmaceutical composition of the

Thiazolidine derivatives or salts thereof as an active ingredient an inhibitor Pim

PROBLEM TO BE SOLVED: To provide compounds which have excellent Pim inhibitory action and are useful as pharmaceuticals.SOLUTION: A compound is a thiazolidine derivative represented by the general formula (1) in the figure, or a salt thereof. (In the formula, X represents O or S; Rrepresents a hydrogen atom or a Calkyl group; Z, Z, Z, Z, Zand Zeach independently represent CH or N; Y represents an optionally substituted, divalent Caromatic hydrocarbon group or the like; Am represents a disubstituted amino group, or an optionally substituted, nitrogen-containing saturated heterocyclic group; and Rand Reach independently represent a hydrogen atom, a halogen atom, an alkyl group or the like.)

Protozoan Parasite Growth Inhibitors Discovered by Cross-Screening Yield Potent Scaffolds for Lead Discovery

Tropical protozoal infections are a significant cause of morbidity and mortality worldwide; four in particular (human African trypanosomiasis (HAT), Chagas disease, cutaneous leishmaniasis, and malaria) have an estimated combined burden of over 87 million disability-adjusted life years. New drugs are needed for each of these diseases. Building on the previous identification of NEU-617 (1) as a potent and nontoxic inhibitor of proliferation for the HAT pathogen (Trypanosoma brucei), we have now tested this class of analogs against other protozoal species: T. cruzi (Chagas disease), Leishmania major (cutaneous leishmaniasis), and Plasmodium falciparum (malaria). Based on hits identified in this screening campaign, we describe the preparation of several replacements for the quinazoline scaffold and report these inhibitors' biological activities against these parasites. In doing this, we have identified several potent proliferation inhibitors for each pathogen, such as 4-((3-chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)-6-(4-((4-methyl-1,4-diazepan-1-yl)sulfonyl)phenyl)quinoline-3-carbonitrile (NEU-924, 83) for T. cruzi and N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl)-7-(4-((4-methyl-1,4-diazepan-1-yl)sulfonyl)phenyl)cinnolin-4-amine (NEU-1017, 68) for L. major and P. falciparum.